Trading in Grail (GRAL) stock remained halted late Wednesday as a Food and Drug Administration panel issued a mixed vote in favor of the company's blood screening test for cancer. The meeting is a key step toward FDA approval for the test, Galleri, which aims to screen asymptomatic people for myriad cancers. In general, it's easier to treat an earlier-stage…